Granted Patent
B2
US 12,201,679 · App. 16/841,635 · Granted Jan 21, 2025
Epitope-targeted peptide immunostimulants
Inventors:
James R. Heath (Seattle, WA); Matthew N. Idso (Seattle, WA); Mario Arrieta-Ortiz (Seattle, WA); Ajay Akhade (Seattle, WA)
Assignee:
Institute for Systems Biology
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed are compounds, compositions, and methods relating to epitope-targeted immunostimulants (EPIs), which comprise a synthetic peptide ligand and an antibody-recruiting moiety. The peptide ligand binds an epitope on a target and the antibody-recruiting moiety recruits antibodies to the target when the EPI is bound to the epitope on the target. Also disclosed are compositions comprising any of the disclosed EPIs. Also disclosed are methods of stimulating an immune reaction to a microorganism or other pathogen in a subject where an EPI is administered to the subject. Also disclosed are methods of identifying the peptide ligand by using multi-omic analysis.
Claims (22)
1. An epitope-targeted immunostimulant (EPI) comprising a cyclic synthetic peptide ligand conjugated or coupled to an antibody-recruiting moiety,
wherein the cyclic synthetic peptide ligand has affinity for MrkA protein exposed on a surface of a target,
wherein the cyclic synthetic peptide ligand comprises an amino acid sequence and a triazole residue, wherein the triazole residue is a 1,4-substituted-1,2,3-triazole residue (Tz4) or a 1,5-substituted-1,2,3-triazole residue (Tz5),
wherein the antibody-recruiting moiety is recognized by an antibody that mediates recognition and phagocytosis of the target by an immune cell, and
wherein the amino acid sequence of the cyclic synthetic peptide ligand is LLFFF (SEQ ID NO:5), ALFFF (SEQ ID NO:7), LAFFF (SEQ ID NO:8), LLAFF (SEQ ID NO:9), HLFFF (SEQ ID NO:13), LLFF(4-fluoro-phenylalanine) (SEQ ID NO:36), LFFF (SEQ ID NO:37), FYTKG (SEQ ID NO:42), EYEGK (SEQ ID NO:43), PWNKG (SEQ ID NO:44), SWTGE (SEQ ID NO:45), RHPGE (SEQ ID NO:46), NRTGP (SEQ ID NO:47), PREGP (SEQ ID NO:48), SNFGP (SEQ ID NO:49), EKTPG (SEQ ID NO:50), KGFPG (SEQ ID NO:51), GGFNA (SEQ ID NO:52), NGPVH (SEQ ID NO:53), WYKGP (SEQ ID NO:54), WDYKG (SEQ ID NO:55), YRHLG (SEQ ID NO:56), GVHRL (SEQ ID NO:57), GVVEK (SEQ ID NO:58), GLTHA (SEQ ID NO:59), SLGLT (SEQ ID NO:60), KPAG (SEQ ID NO:61), AKPEP (SEQ ID NO:62), EWVSA (SEQ ID NO:63), EFSGV (SEQ ID NO:64), DGTAL (SEQ ID NO:65), VVNLP (SEQ ID NO:66), TPNLP (SEQ ID NO:67), RPEGP (SEQ ID NO:68), or LLFF (SEQ ID NO:73).
2. The EPI of claim 1 , wherein the amino acid sequence of the cyclic synthetic peptide ligand is LLFFF (SEQ ID NO:5).
3. An epitope-targeted immunostimulant (EPI) comprising a cyclic synthetic peptide ligand conjugated or coupled to an antibody-recruiting moiety,
wherein the cyclic synthetic peptide ligand has affinity for Staphylococcus aureus peptidoglycan exposed on a surface of a target,
wherein the cyclic synthetic peptide ligand comprises an amino acid sequence and a triazole residue, wherein the triazole residue is a 1,4-substituted-1,2,3-triazole residue (Tz4) or a 1,5-substituted-1,2,3-triazole residue (Tz5),
wherein the antibody-recruiting moiety is recognized by an antibody that mediates recognition and phagocytosis of the target by an immune cell, and
wherein the amino acid sequence of the cyclic synthetic peptide ligand is kpdew (SEQ ID NO:23), akkrp (SEQ ID NO:34), athsl (SEQ ID NO:19), GnGdv (SEQ ID NO:20), pkdew (SEQ ID NO:21), peeGt (SEQ ID NO:24), evetG (SEQ ID NO:25), kadhp (SEQ ID NO:26), kndp (SEQ ID NO:27), Glhtd (SEQ ID NO:28), sdlpr (SEQ ID NO:29), pdedw (SEQ ID NO:30), aGpve (SEQ ID NO:31), akGGp (SEQ ID NO:32), aGkGp (SEQ ID NO:33), fdeGe (SEQ ID NO:69), fdeGp (SEQ ID NO:70), or ldeGp (SEQ ID NO:71).
4. The EPI of claim 3 , wherein the amino acid sequence of the cyclic synthetic peptide ligand is kpdew (SEQ ID NO:23) or akkrp (SEQ ID NO:34).
5. The EPI of claim 1 or 3 , wherein the triazole residue is a 1,4-substituted-1,2,3-triazole residue (Tz4).
6. The EPI of claim 1 or 3 , wherein the triazole residue is a 1,5-substituted-1,2,3-triazole residue (Tz5).
7. The EPI of claim 1 or 3 , wherein the antibody-recruiting moiety is an immunogen endogenously recognized by a mammalian immune system.
8. The EPI claim 1 or 3 , wherein the antibody-recruiting moiety is an immunogen endogenously recognized by a human immune system.
9. The EPI of claim 1 or 3 , wherein the antibody-recruiting moiety is 2,4-dinitrophenyl (DNP), alpha-galactose, galactose(alpha1-3)galactose, beta-lactam, 1,3-diketone, avidin, fluorescein, fluorescein-DNP, or nitrophenol.
10. The EPI of claim 1 or 3 , wherein the cyclic synthetic peptide ligand is comprised in a multi-ligand,
wherein the multi-ligand further comprises a second ligand covalently linked to the cyclic synthetic peptide ligand.
11. A pharmaceutical composition comprising the EPI of claim 1 or 3 and a pharmaceutically acceptable carrier.
12. The EPI of claim 1 or 3 , wherein the cyclic synthetic peptide ligand has the structure:
wherein X 1 -X 2 -X 3 -X 4 -X 5 represents the amino acid sequence of the cyclic synthetic peptide ligand, wherein X 1 -X 2 -X 3 -X 4 -X 5 is in the N-terminus to C-terminus direction.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 15, 2020
From: HEATH, JAMES R.; IDSO, MATTHEW N.; ARRIETA-ORTIZ, MARIO; AKHADE, AJAY
To: INSTITUTE FOR SYSTEMS BIOLOGY
Reel/Frame 052938/0450 →
Continuity (2)
Provisional Application
62830193
· Apr 5, 2019
References Cited (191)
US 4899755A
· Lauffer
· 1990
[cited by applicant]
US 5474756A
· Tweedle
· 1995
[cited by applicant]
US 5547668A
· Kranz
· 1996
[cited by applicant]
US 5846519A
· Tweedle
· 1998
[cited by applicant]
US 6143274A
· Tweedle
· 2000
[cited by applicant]
US 6566088B1
· Mcknight
· 2003
[cited by applicant]
US 8710180B2
· Pitram
· 2014
[cited by applicant]
US 8841083B2
· Heath
· 2014
[cited by applicant]
US 8906830B2
· Agnew
· 2014
[cited by applicant]
US 9188584B2
· Agnew
· 2015
[cited by applicant]
US 9221889B2
· Pitram
· 2015
[cited by applicant]
US 9239332B2
· Heath
· 2016
[cited by applicant]
US 9913875B2
· Farrow
· 2018
[cited by applicant]
US 20060153839A1
· Mohamed
· 2006
[cited by applicant]
US 20110177109A1
· Smith, III
· 2011
[cited by applicant]
US 20120252071A1
· Greif
· 2012
[cited by applicant]
US 20150344523A1
· Deyle
· 2015
[cited by applicant]
US 20200407712A1
· Boyd
· 2020
[cited by applicant]
EP 2719706
· 2014
[cited by applicant]
WO 1986006605
· 1986
[cited by applicant]
WO 1991003200
· 1991
[cited by applicant]
WO 1995028179
· 1995
[cited by applicant]
WO 1995028967
· 1995
[cited by applicant]
WO 1996023526
· 1996
[cited by applicant]
WO 1997036619
· 1997
[cited by applicant]
WO 1998018496
· 1998
[cited by applicant]
WO 1998018497
· 1998
[cited by applicant]
WO 1998046612
· 1998
[cited by applicant]
WO 1999017809
· 1999
[cited by applicant]
WO 9921576
· 1999
[cited by applicant]
WO 02083064
· 2002
[cited by applicant]
WO 03006620
· 2003
[cited by applicant]
WO 2005113762
· 2005
[cited by applicant]
WO 2007050963
· 2007
[cited by applicant]
WO 2009051555
· 2009
[cited by applicant]
WO 2009105746
· 2009
[cited by applicant]
WO 2009155420
· 2009
[cited by applicant]
WO 2010135431
· 2010
[cited by applicant]
WO 2011057347
· 2011
[cited by applicant]
WO 2012106651
· 2012
[cited by applicant]
WO 2012106671
· 2012
[cited by applicant]
WO 2013009869
· 2013
[cited by applicant]
WO 2013033561
· 2013
[cited by applicant]
WO 2013034982
· 2013
[cited by applicant]
WO WO2014056813A1
· 2014
[cited by examiner]
WO 2014074907
· 2014
[cited by applicant]
WO 2014205317
· 2014
[cited by applicant]
WO 2016038565
· 2016
[cited by applicant]
WO 2017011769
· 2017
[cited by applicant]
WO 2017176769
· 2017
[cited by applicant]
WO 2018064597
· 2018
[cited by applicant]
WO WO2018111580A1
· 2018
[cited by examiner]
WO 2018170096
· 2018
[cited by applicant]
WO 2018200551
· 2018
[cited by applicant]
WO 2020127227
· 2020
[cited by applicant]
Lai et al. Epitope-Targeted Macrocyclic Peptide Ligand with Picomolar Cooperative Binding to Interleukin-17F. Chemistry—A European Journal. 2018, vol. 24, pp. 3760-3767. (Year: 2018).
[cited by examiner]
Agnew, et al., “Iterative In Situ Click Chemistry Creates Antibody-like Protein-Capture Agents”, Angew. Chem. Int. Ed. Engl., 48:4944-4948 (2009).
[cited by applicant]
Agnew, et al., “Protein-Catalyzed Capture Agents”, Chem. Rev., 119:9950-70 (2019).
[cited by applicant]
Alcántar-Curiel, et al., “Association of Antibiotic Resistance, Cell Adherence, and Biofilm Production with the Endemicity of Nosocomial Klebsiella pneumoniae”, Biomed. Res. Int., 2018:7012958 (2018).
[cited by applicant]
Alexander, et al., “Intracranial black-blood MR angiography with high-resolution 3D fast spin echo”, Magn. Reson. Med., 40:298-310 (1998).
[cited by applicant]
Altschul, et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”, Nucleic Acids Res., 25:3389-402 (1997).
[cited by applicant]
Barnes, et al., “Smartphone-based pathogen diagnosis in urinary sepsis patients”, EBioMedicine, 36:73-82 (2018).
[cited by applicant]
Berry, et al., “Renal Sodium Gradient Orchestrates a Dynamic Antibacterial Defense Zone”, Cell 170(5):860-3 (2017).
[cited by applicant]
Brinkworth, et al., “Identification of Outer Membrane and Exoproteins of Carbapenem-Resistant Multilocus Sequence Type 258 Klebsiella pneumoniae”, PLoS One, 10:e0123219 (2015).
[cited by applicant]
Brown, et al., “Antibacterial drug discovery in the resistance era”, Nature, 529:336-43 (2016).
[cited by applicant]
Bunck, et al., “Modulating the Folding Landscape of Superoxide Dismutase 1 with Targeted Molecular Binders”, Angew Chemie, 130:6320-3 (2018).
[cited by applicant]
Cahill, et al., “Klebsiella pneumoniae O antigen loss alters the outer membrane protein composition and the selective packaging of proteins into secreted outer membrane vesicles”, Microbiol Res., 180:1-10 (2015).
[cited by applicant]
Claverie, “Information enhancement methods for large scale sequence analysis”, Comput. Chem., 17:191-201 (1993).
[cited by applicant]
Coppock, et al., “Protein Catalyzed Capture Agents with Tailored Performance for in Vitro and in Vivo Applications”, Pept. Sci., 108(2):e22934 (2016).
[cited by applicant]
Czaplewski, et al., “Alternatives to antibiotics—a pipeline portfolio review”, Lancet. Infect. Dis., 16:239-51 (2016).
[cited by applicant]
Das, et al., “A General Synthetic Approach for Designing Epitope Targeted Macrocyclic Peptide Ligands”, Angew Chemie Int. Ed., 54:13219-24 (2015).
[cited by applicant]
Digiandomenico, et al., “Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening”, J. Exp. Med., 209(7):1273-87 (2012).
[cited by applicant]
Dotiwala, et al., “Granzyme B Disrupts Central Metabolism and Protein Synthesis in Bacteria to Promote an Immune Cell Death Program”, Cell, 171:1125-37 (2017).
[cited by applicant]
Edelman, et al., “Extracranial carotid arteries: evaluation with “black blood” MR angiography”, Radiology, 177:45-50 (1990).
[cited by applicant]
Fair, et al., “Antibiotics and Bacterial Resistance in the 21st Century”, Perspect. Medicin. Chem., 6:25-64. (2014).
[cited by applicant]
Farrow, et al., “Epitope-Targeting of Tertiary Protein Structure Enables Target-Guided Synthesis of a Potent in Cell Inhibitor of Botulinum Neurotoxin”, Angew. Chemie Int. Ed., 54(24):7114-9 (2015).
[cited by applicant]
Fura, et al., “D-Amino Acid Mediated Recruitment of Endogenous Antibodies to Bacterial Surfaces”, ACS Chem. Biol., 9:1480-9 (2014).
[cited by applicant]
Fura, et al., “Dipeptide-Based Metabolic Labeling of Bacterial Cells for Endogenous Antibody Recruitment”, ACS Infec. Dis., 2(4):302-309 (2016).
[cited by applicant]
Giandomenico, et al., “A multifunctional bispecific antibody protects against Pseudomonas aeruginosa”, Sci. Transl. Med., 6:262ra155 (2014).
[cited by applicant]
Goodrich, et al., “A quantitative study of ramped radio frequency, magnetization transfer, and slab thickness in three-dimensional time-of-flight magnetic resonance angiography in a patient population”, Invest. Radia., …
[cited by applicant]
Guilhen, et al., “Transcriptional profiling of Klebsiella pneumoniae defines signatures for planktonic, sessile and biofilm-dispersed cells”, BMC Genomics, 17:237(2016).
[cited by applicant]
Hancock, et al., “Modulating Immunity as a Therapy for Bacterial Infections”, Nat. Rev. Microbio., 10:243-54 (2012).
[cited by applicant]
Kavvas, et al., “Machine Learning and Structural Analysis of Mycobacterium tuberculosis Pan-genome Identifies Genetic Signatures of Antibiotic Resistance”, Nat. Commun., 29:4306 (2018).
[cited by applicant]
Krishnamurthy, et al., “Promotion of opsonization by antibodies and phagocytosis of Gram-positive bacteria by a bifunctional polyacrylamide”, Biomaterials, 27:3663-74 (2006).
[cited by applicant]
Lai, et al., “Epitope Targeted Macrocyclic Peptide Ligand with Picomolar Cooperative Binding to Interleukin-17F”, Chem—A Eur J., 24:3760-7 (2018).
[cited by applicant]
Lee, et al., “Network Integrative Genomic and Transcriptomic Analysis of Carbapenem-Resistant Klebsiella pneumoniae Strains Identifies Genes for Antibiotic Resistance and Virulence”, mSystems, 4:e00202-19 (2019).
[cited by applicant]
Lorenz, et al., “Functional Antibodies Targeting IsaA of
[cited by applicant]
Lu, et al., “Beyond binding: antibody effector functions in infectious diseases”, Nat. Rev. Immunol., 18:46-61 (2019).
[cited by applicant]
Lu, et al., “Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential”, Mol. Pharm., 4(5):2432-43 (2007).
[cited by applicant]
Martin, et al., “Colonization, Infection, and the Accessory Genome of Klebsiella pneumoniae”, Front Cell Infect. Microbiol., 8:4 (2018).
[cited by applicant]
Mccarthy, et al., “Allosteric Inhibitor of KRas Identified Using a Barcoded Assay Microchip Platform”, Anal Chem., 90:8824-30 (2018a).
[cited by applicant]
Mccarthy, et al., “Phage Display of Dynamic Covalent Binding Motifs Enables Facile Development of Targeted Antibiotics”, J. Am. Chem. Soc., 140:6137-45 (2018b).
[cited by applicant]
Mcenaney, et al., “Antibody-Recruiting Molecules: An Emerging Paradigm for Engaging Immune Function in Treating Human Disease”, ACS Chem. Biol., 7(7):1139-1151 (2012).
[cited by applicant]
Meyers and Miller, “Optimal alignments in linear space”, Comp. Applic. Biol. Sci., 4(1):11-17 (1988).
[cited by applicant]
Murelli, et al., “Chemical Control over Immune Recognition: A Class of Antibody-Recruiting Small Molecules That Target Prostate Cancer”, J. Am. Chem. Soc., 131:17090-2 (2009).
[cited by applicant]
Paczosa, et al., “Klebsiella pneumoniae: Going on the Offense with a Strong Defense”, Microbiol. Mol. Biol. Rev., 80:629-61 (2016).
[cited by applicant]
Pelfrene, et al., “Monoclonal antibodies as anti-infective products: a promising future”, Clin. Microbiol. Infect., 25:60-4 (2019).
[cited by applicant]
Prevention C for DCA. Antibiotic Resistance Threats in the United States, 2013. Atlanta, Georgia; 2013.
[cited by applicant]
Roope, et al., “The challenge of antimicrobial resistance: What economics can contribute”, Science, 364:41 (2019).
[cited by applicant]
Sabulski, et al., “Immuno-targeting of
[cited by applicant]
Saphire, et al., “Antibody-mediated protection against Ebola virus”, Nat. Immunol., 19:1169-78 (2018).
[cited by applicant]
Tacconelli, et al., “Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis”, Lancet Infect. Dis., 18:318-27 (2018).
[cited by applicant]
Tzouvelekis, et al., “Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions”, Clin. Microbiol. Rev., 25:682-707 (2012).
[cited by applicant]
Ventola, “The Antibiotic Resistance Crisis Part 1□ Causes and Threats”, Pharm. Ther., 40:277-83 (2015).
[cited by applicant]
Wang, et al., “Anti-MrkA monoclonal antibodies reveal distinct structural and antigenic features of MrkA”, PLoS One, 12:e017059 (2017).
[cited by applicant]
Wen, et al., “G-protein-coupled formyl peptide receptors play a dual role in neutrophil chemotaxis and bacterial phagocytosis”, Mol. Biol. Cell., 30:346-56 (2019).
[cited by applicant]
Wootton, and Federhen, “Statistics of local complexity in amino acid sequences and sequences databases”, Comput. Chem., 17(2):149-63 (1993).
[cited by applicant]
Muller, et al., “Folic acid conjugates for nuclear imaging of folate receptor-positive cancer”, J. Nucl. Med., 52(1): 1-4 (2011).
[cited by applicant]
O'Shannessy, et al., “Characterization of the human folate receptor alpha via novel antibody-based probes”, Oncotarget, 2(12):1227-1243 (2011).
[cited by applicant]
Artali, et al., “A molecular dynamics study of human serum albumin binding sites”, II Farmaco, 60:485-495 (2005).
[cited by applicant]
Bianchi et al., “Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates”, PNAS, 107(23): 10655-10660 (2010).
[cited by applicant]
Boersma, “Gaining knowledge of single carbon chains”, Theory of condensed matter, Radboud Univ. Nijmegen, 18 pages (2011).
[cited by applicant]
Chan, et al., “Dual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy”, Scientific Reports, 6:35247, 13 pages (2016).
[cited by applicant]
Chattopadhyay, et al., “Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8+ T cells with peptide-major histocompatibility complex class I tetramers”, Cytometry Part A, 73(11): 1001-…
[cited by applicant]
Chauhan, et al. “The Taming of the Cell Penetrating Domain of the HIV Tat: Myths and Realities”, J. Control Release, 117(2): 148-162 (2007).
[cited by applicant]
Chen, et al., “Fusion protein linkers: property, design and functionality”, Adv. Drug Deliv. Rev., 65(10): 1357-1369 (2013).
[cited by applicant]
Cheong, et al., “A patent review of IDO1 inhibitors for cancer”, Expert Opinion on Therapeutic Patents, 28(4):317-330 (2018).
[cited by applicant]
Choksi, et al., “A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model”, Biology Of Blood And Marrow Transplantation,…
[cited by applicant]
Coppock, et al., “Peptide-based protein capture agents with high affinity, selectivity, and stability as antibody replacements in biodetection assays”, Proc. of SPIE, 9107:910711-1 (2014).
[cited by applicant]
Dieck, et al., “Development of bispecific molecules for the in situ detection of protein-protein interactions and protein phosphorylation”, Cell & Biology, 21:357-368 (2014).
[cited by applicant]
Eiber, et al., “Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy”, The Journal Of Nuclear Medicine, 58(Supplement 2):67S-76S (2017).
[cited by applicant]
Fisher, et al., “Trivalent Gd-DOTA reagents for modification of proteins”, RSC Adv., 5: 96194-96200 (2015).
[cited by applicant]
Fitzer-Attas , et al., “Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the Variable Domain recept”, J. Immunol., 160(1):145-154 (1998).
[cited by applicant]
Gao, et al., “Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2”, Nature, 387:630-4 (1997).
[cited by applicant]
Gen Bank: AAH25715.1 , “CD8a molecule [
[cited by applicant]
Handl, et al., “Hitting multiple targets with multimeric ligands”, Expert Opin. Ther. Targets, 8(6):565-586 (2004).
[cited by applicant]
Hill, et al., “Constraining Cyclic Peptides to Mimic Protein Structure Motifs”, Angewandte Chemie, 53(48):13020-13041 (2014).
[cited by applicant]
Hirai, et al., “MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo”, Molecular Cancer Therapeutics, 9(7): 1956-1967 (20…
[cited by applicant]
Hudson, et al., “Multiplex epitope mapping using bacterial surface display reveals both linear and conformational epitopes”, Scientific Reports, 2(706):1-9 (2012).
[cited by applicant]
Josan, et al., “Cell-specific targeting by heterobivalent ligands”, Bioconjug Chem., 22(7): 1270-1278 (2011).
[cited by applicant]
Lai, et al., “Epitope-Targeted Macrocyclic Peptide Ligand with Picomolar Cooperative Binding to Interleukin-17F”, Chemistry, 24(15):3760-3767 (2018).
[cited by applicant]
Li, et al., “Identification of the CD8 DE Loop as a Surface Functional Epitope”, The J. of Biological Chem., 273(36):16422-16445 (1998).
[cited by applicant]
Lin, et al., “Inhibition of HIV-1 Tat-mediated transcription by a coumarin derivative, BPRHIV001, through the Akt pathway”, Journal of Virology, 85(17): 9114-9126 (2011).
[cited by applicant]
Lindlsey, et al., “The P13K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors”, Current Cancer Drug Targets, 8: 7-18 (2008).
[cited by applicant]
Ma, et al., “A cyclic peptide-polymer probe for the detection of Clostridium botulinum neurotoxin serotype A”, Toxicon, 47(8):901-908 (2006).
[cited by applicant]
Mabry, et al., “Engineering of stable bispecific antibodies targeting IL-17 A and IL-23”, Protein Engineering, Design & Selection, 23(3):115-127 (2010).
[cited by applicant]
Macraild et al., “Antibody Recognition of Disordered Antigens”, Structure 24:148-157, (2016).
[cited by applicant]
Macraild et al., “Conformational Dynamics and Antigenicity in the Disordered Malaria Antigen Merozoite Surface Protein 2”, Plos One, 13 pages (2015).
[cited by applicant]
Mamidyala et al., In situ click chemistry: probing the binding landscapes of biological molecules, Chemical Society Reviews, 39(4):1252-1261 (2010).
[cited by applicant]
Manea, et al., “Antibody Recognition and Conformational Flexibility of a Plaque-Specific-Amyloid Epitope Modulated by Non-native Peptide Flanking Regions”, J. Med. Chem., 51(5):1150-1161 (2008).
[cited by applicant]
Matsuura, “Identification of conformational neutralizing epitopes on the capsid protein of canine calicivirus”, Journal of General Virology, 82:1695-1702 (2001).
[cited by applicant]
Melenhorst et el., “Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers”, J Immunol Methods, 338(1-2): 31-39 (2008).
[cited by applicant]
Merriam-Webster online definition of “correspond” downloaded Jun. 29, 2020 from internet, https://www.merriam-webster.com/dictionary/correspond (Year: 2020).
[cited by applicant]
Millward, et al., “In situ click chemistry: from small molecule discovery to synthetic antibodies”, Integr. Biol (Camb)., 5(1): 87-95 (2013).
[cited by applicant]
Millward, et al., “Iterative in situ click chemistry assembles a branched capture agent and allosteric inhibitor for Akt1”, JACS, 133(45):18280-18288 (2011).
[cited by applicant]
Miossec, “Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice”, RMD Open, 3(1): e000284 (2017).
[cited by applicant]
Mor, et al., Mimicking the Structure of the V3 Epitope Bound to HIV-1 Neutralizing Antibodies, Biochemistry, 48(15):3288-3303 (2009).
[cited by applicant]
Muller, et al., “DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid-Targeted 177Lu-Radionuclide Tumor Therapy in Mice”, The Journal Of Nuclear Medicine, 54(1):124-131 (2013).
[cited by applicant]
Nag et al., “A chemical epitope-targeting strategy for protein capture agents: the serine 474 epitope of the kinase Akt2”, Angewandte Chemie International Edition, 52:13975-13979 (2013).
[cited by applicant]
Pansca, et al., “Structural disorder in eukaryotes”, PLoS One, www.plosone.org Apr. 1, 2012, 7(4): e34687, 10 pages (2012).
[cited by applicant]
Pfeilsticker, et al., “A cocktail of thermally stable, chemically synthesized capture agents for the efficient detection of anti-gp41 antibodies from human sera”, PloS One, 8(10):Article No. e76224, 5 pages (2013).
[cited by applicant]
Saito, et al., “Identification of anti-CD98 antibody mimotopes for inducing antibodies with antitumor activity by mimotope immunization”, Cancer Science, 105(4): 396-401 (2014).
[cited by applicant]
Sarbassov, et al., “Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex”, Science, American Association for The Advancement Of Science, 307(5712): 1098-1101 (2005).
[cited by applicant]
Schweinsberg, et al., “Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors”, Bioconjugate Chem., 19(12):2432-2439 (2008).
[cited by applicant]
Son, et al., “New Cyclic Lipopeptides of the Iturin Class Produced by Saltern-Derived
[cited by applicant]
Subramanyam, et al., “Inhibition of Protein Kinase Akt1 by Apoptosis Signal-regulating Kinase-1 (ASK1) Is Involved in Apoptotic Inhibition of Regulatory Volume Increase”, Journal Of Biological Chemistry, 285(9): 6109-61…
[cited by applicant]
Tang et al., “Chimeric molecules facilitate the degradation of androgen receptors and repress the growth of LNCaP cells”, Asian Journal of Andrology, 11(1): 119-126 (2009).
[cited by applicant]
Tao, et al., “Expression, purification and identification of an immunogenic fragment in the ectodomain of prostate-specific membrane antigen”, Experimental And Therapeutic Medicine, 11(3): 747-752 (2016).
[cited by applicant]
Todorova, et al., “Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induces after immunization with gene-based vaccines”, Anticancer Research, 25: 4727-4732 (2005).
[cited by applicant]
Torres, et al., “A revolutionary therapeutic approach for psoriasis: bi specific biological agents”, Expert Opinion On Investigational Drugs, 25(7): 751-754 (2016).
[cited by applicant]
Wang, et al., “Epitope Mapping Using Phage-Display Random Fragment Libraries”, Epitope Mapping Protocols, Methods in Molecular Biology, 524: 315-332 (2009). Abstract Only.
[cited by applicant]
Wang, et al., “Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent 90 Y-DOTA-EB-MCG”, Bioconjugate Chemistry, 29(7): 2309-2315 (2018).
[cited by applicant]
Wooldridge, et al., “Tricks with tetramers: how to get the most from multimeric peptide-MHC”, Immunology, 126:147-164 2009 (2009).
[cited by applicant]
Zhang, et al., “Structure and function of interleukin-17 family cytokines”, Protein & Cell, 2(1): 26-40 (2011).
[cited by applicant]
Agalave, et al., “Click chemistry: 1,2,3-triazoles as pharmacophores”, Chem. Asian J., 6:(10)2696-27018 (2011).
[cited by applicant]
Almehdi, et al., “SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies”, Infection, 49: 855-876 (2021).
[cited by applicant]
BPS Bisoscience: INCB024360 Analog Data Sheet (2012).
[cited by applicant]
Glaven, “Linking Single Domain Antibodies that Recognize Different Epitopes on the Same Target”, Biosensors, 2:43-56 (2012).
[cited by applicant]
He, et al., “Vaccine design based on 16 epitopes of SARS-CoV-2 spike protein”, Journal of Medical Virology, 93:2115-2131 (2021).
[cited by applicant]
Kirszbaum, et al., “The alpha-chain of murine CD8 lacks an invariant Ig-like disulfide bond but contains a unique intrachain loop instead”, J. Immunol., 142(11):3931-6 (1989).
[cited by applicant]
Koonin, et al., “Sequence—Evolution—Function: Computational Approaches in Comparative Genomics”, Boston: Kluwer Academic; 2003, Chapter 2 Evolutionary Concept in Genetics and Genomics (2003).
[cited by applicant]
Reeck, et al., “Homolgy' in Proteins and Nucleic Acids: A Terminology Muddle and a Way out of it”, Cell, 50:667 (1987).
[cited by applicant]
Smith, et al., “Zinc mediated azide-alkyne ligation to 1,5- and 1,4,5-substituted 1,2,3-triazoles”, Org. Lett., 15(18):4826-4829 (2013).
[cited by applicant]
Sormanni, et al., “Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins”, PNAS, 112(32):9902-9907 (2015).
[cited by applicant]
Sormanni, etal., “Supporting Information”, PNAS, 112(32):1-10 (2015). Supplemental Materials.
[cited by applicant]
Testa, et al., “CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies”, Biomarker Research, 2:4 (2014).
[cited by applicant]
Wang, et al., “Structural basis of the CD8 alpha beta/MHC class I interaction: focused recognition orients CD8 beta to a T cell proximal position”, J. Immunol., 183(4):2554-64 (2009).
[cited by applicant]
Yang, et al., “Structural biology of SARS-CoV-2 and implications for therapeutic development”, Nature Reviews, 19:685-700 (2021).
[cited by applicant]
Nakano et al., “Amino Acid Sequence of Cytochrome C-553 from Desulfovibrio vulgaris Miyazaki” vol. 258 No. 20 Issue of Oct. 25 pp. 12409-12412(1983).
[cited by applicant]
Murphy et al,. “Janeway's Immunobiology, 9th edition”, pp. 150-151 (2017).
[cited by applicant]